


02/15/00



PATENT

Docket No. 2653/28

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ASSISTANT COMMISSIONER
FOR PATENTS
Washington, DC 20231

SIR:

Transmitted herewith for filing under 37 C.F.R. § 1.53 is the patent application of

Inventors : Jonathan L. TILLY and Richard N. KOLESNICK
Serial No. : (Unassigned)
Filed : (Herewith)
For : PROTECTION OF THE FEMALE REPRODUCTIVE SYSTEM
FROM NATURAL AND ARTIFICIAL INSULTS

Enclosed are:

1. 28 sheets of specification, 5 sheets of claims, 1 sheet of abstract; and 3 sheets of a list of references;
2. 4 sheets of drawings;
3. Charge Deposit Account No. 11-0600 in the amount of \$1,218.00 representing the fee under 37 C.F.R. §§ 1.16(a), (b) and (c).

The filing fee has been calculated as shown below:

For	No. Filed	No. Extra	Rate	Fee
Basic Fee				\$690.00
Total Claims	45 - 20 =	25	\$ 18.00	\$450.00
Independent Claims ..	4 - 3 =	1	\$ 78.00	\$ 78.00
TOTAL FEE				<u>\$1,218.00</u>

The Commissioner is hereby authorized to charge payment of the total fee of \$1,218.00 and any additional fees associated with this communication or credit any overpayment to Deposit Account No. 11-0600.



The Commissioner is further authorized to charge payment of any patent application processing fees under 37 C.F.R. §1.17 or any filing fees under 37 C.F.R. §1.16 for presentation of extra claims during the pendency of this application or credit any overpayment to Deposit Account No. 11-0600. A copy of this sheet is enclosed for that purpose.

Respectfully submitted,



Houri Khalilian
(Reg. No. 39,546)

Dated: 15 February 2000

KENYON & KENYON
1500 K Street, N.W., Suite 700
Washington, DC 20005

Tel: (202) 220-4200
Fax: (202) 220-4201

318718/2653/28

**United States Patent Application
For**

**Protection of The Female Reproductive System
From Natural and Artificial Insults**

Inventors:

Jonathan L. Tilly

Richard N. Kolesnick

Prepared By:

**Kenyon & Kenyon
1500 K Street, N.W.
Washington, D.C. 20005
(202) 220-4200**

Field of the Invention

The present invention relates to methods for protecting female reproductive system against natural or artificial insults by administering a composition comprising an agent that antagonizes one or more acid sphingomyelinase (*ASMase*) gene products. In particular, this invention relates to a method of protecting ovaries from cancer therapy regimens, chemotherapy and radiotherapy, by administering to women a composition containing sphingosine-1-phosphate, or an analog thereof, prior to the therapy. Methods to enhance ovarian functions, ameliorate symptoms of menopause, and improve the success of *in vitro* fertilization are also disclosed.

I. Background of the Invention

Female gonads house a finite number of meiotically-arrested germ cells (oocytes) enclosed within primordial follicles that serve as the stockpile of eggs released at ovulation at each menstrual cycle for potential fertilization. Gougeon, *Endocr Rev.* 17, 121 (1996); Morita & Tilly, *Dev. Biol.* 213 (1999). Once depleted, the ovarian germ cell pool cannot be replenished. Thus, exposure of women to a wide spectrum of agents that damage the ovary, such as chemotherapeutic agents and radiotherapy, generally leads to premature menopause and irreversible sterility. Waxman, *Soc. Med.* 76, 144 (1983); Familiari *et al.*, *Hum. Reprod.* 8, 2080 (1993); Ried & Jaffe, *Semin. Roentgenol.* 29, 6 (1994); and Reichman & Green,

Monogr. Natl. Cancer Inst. 16, 125 (1994).

Apoptotic cell death plays a fundamental role in normal germ cell endowment and follicular dynamics in the ovary. Tilly & Ratts, *Contemp. Obstet. Gynecol.* 41, 59 (1996); Tilly, *Rev. Reprod.* 1, 162 (1996); and Tilly *et al.*, *Cell Death Differ.* 4, 180 (1997). Cell fate in the ovary is likely dependent on the actions of several proteins recently identified as key determinants of cell survival or death (Adams & Cory, *Science* 281, 1322 (1998); Green, *Cell* 94, 695 (1998); Thornberry & Lazebnik, *Science* 281, 1312 (1998); Reed, *Oncogene* 17, 3225 (1998); Korsmeyer, *Cancer Res.* 59, 1693 (1999). Among these identified in the ovary are p53 (Tilly *et al.*, *Endocrinology* 136, 1394 (1995); Keren-Tal *et al.*, *Exp. Cell Res.* 218, 283 (1995); and Makrigiannakis *et al.*, *J. Clin. Endocrinol. Metab.* 85, 449 (2000)), members of the *bcl-2* gene family (Tilly *et al.*, *Endocrinology* 136-232 (1995); Ratts *et al.*, *Endocrinology* 136, 3665 (1995); Knudson *et al.*, *Science* 270, 99 (1995); Perez *et al.*, *Nature Med.* 3, 1228 (1997); Kugu *et al.*, *Cell Death Differ.* 5, 67 (1998); Perez *et al.*, *Nature Genet.* 21, 200 (1999), and members of the *caspase* gene family (Flaws *et al.*, *Endocrinology* 136, 5042 (1995); Perez *et al.*, *Nature Med.* 3, 1228 (1997); Maravei *et al.*, *Cell Death Differ.* 4, 707 (1997); Kugu *et al.*, *Cell Death Differ.* 5, 67 (1998); Boone & Tsang, *Biol. Reprod.* 58, 1533 (1998); Bergeron *et al.*, *Genes Dev.* 13, 1304 (1998); and Perez *et al.*, *Mol. Hum Reprod.* 5, 414 (1999)).

In addition, ceramide, a recently identified lipid second messenger associated with cell death signaling (Spiegel *et al.*, *Curr. Opin. Cell Biol.* 8, 159 (1996); Hannun, *Science* 274, 1855(1996); and Kolesnick & Kronke, *Annu. Rev. Physiol.* 60, 643 (1998)) has been implicated in the induction of apoptosis in the ovary (Witty *et al.*, *Endocrinology* 137, 5269 (1996); Kaipia *et al.*, *Endocrinology* 137, 4864(1996); and Martimbeau & Tilly, *Clin.*

Endocrinol. 46, 241(1997)).

Since the initial discovery of the sphingomyelin pathway, numerous studies have been published on the potential role of ceramide in signaling cell death (Hannun, (1996) *id.*; and Kolesnick & Kronke (1998) *id.* It is now known that ceramide can also be metabolized via ceramidase to sphingosine, which is then phosphorylated by sphingosine kinase to generate sphingosine-1-phosphate (S1P) (Cuvillier *et al.*, *Nature* 381, 800 (1996); Spiegel *et al.*, *Ann. N.Y. Acad. Sci* 845, 11 (1998); and Spiegel, *J. Leukoc. Biol.* 65, 341 (1999)).

In some cell types, S1P can effectively counterbalance stress-kinase activation and apoptosis induced by membrane-permeant ceramide analogs or external stressors known to work through elevations in intracellular ceramide levels. Therefore, a rheostat model has been proposed in which cell fate is controlled by shifts in the balance between ceramide and S1P levels. However, the physiologic importance of ceramide, and that of sphingomyelin hydrolysis as a whole, in activating developmental or homeostatic paradigms of apoptosis have recently been questioned by some investigators (Hofmann & Dixit, *Trends Biochem. Sci* 23, 374 (1998); and Watts *et al.*, *Cell Death Differ.* 6, 105 (1999)). In particular, Hofmann *et al.*, describe a lack of developmental defects that should be the consequence of impaired apoptosis in the acid sphingomyelinase (*ASMase*) gene knockout mouse as substantive evidence against a role for *ASMase*-catalyzed sphingomyelin hydrolysis and ceramide in signaling cell death (Kolesnick & Kronke (1998) *id.*)

Earlier studies using pharmacologic and genetic approaches have shown that several other components of the programmed cell death regulatory pathway in oocytes, including Bcl-2 family members (Ratts *et al.*, *Endocrinology* 136, 3665 (1995); Perez *et al.*, *Nat. Med.* 3, 1228 (1997); Morita *et al.*, *Mol. Endocrinol.* 13, 841 (1999); Perez *et al.*, *Nat. Genet.* 21,

200 (1999)); and caspases (Perez *et al.*, (1997) *id.*; Bergeron *et al.*, *Genes Dev.* 12, 1304 (1998)), are required for oocyte survival or death. However, cell lineage specificity will certainly be an important issue to consider based on observations that p53, a classic signaling molecule for cancer therapy-induced tumor cell destruction (Ko & Prives, *Genes Dev.* 10, 1054 (1996); and Ding *et al.*, *Crit. Rev. Oncog.* 9, 83 (1998)), is completely dispensable for oocyte death initiated by cancer therapy (Perez *et al.*, (1997) *id.*)

Although the sensitivity of oocytes to cancer therapy, and the potential role of ceramide in signaling cell death are reported, as evidenced above, little is known regarding the mechanisms responsible for female germ cell destruction. Recently, it has been shown that female mouse oocytes undergo a type of cell death, referred to as apoptosis, when exposed *in vitro* to a prototypical anti-cancer drug (doxorubicin, 14-hydroxydaunorubicin, Adriamycin®). Perez *et al.*, (1997) *id.* Moreover, it is shown that culture of mouse oocytes *in vitro* with sphingosine-1-phosphate protected the oocytes from death induced by subsequent doxorubicin exposure. However, the protection was only tested *in vitro* with only a single drug, and thus *in vivo* application remained questionable.

The present invention is the first to show that protection of the ovaries from natural or artificial insults is achieved *in vivo*, and that this protection is accomplished by administration of a composition containing an agent that antagonizes activity or expression of one or more acid sphingomyelinase (*ASMase*) gene products. The invention demonstrates that such agents have promising therapeutic effects in combating ovarian failure, thus, preserving fertility and normal ovarian functions under various adverse conditions.

II. Summary of the Invention

5 The present invention provides a method of protecting female reproductive system against a natural or an artificial insult comprising: administering a composition comprising an agent that antagonizes one or more acid sphingomyelinase (*ASMase*) gene product, in an amount sufficient to protect said female reproductive system from normal or pre-mature aging or destruction caused by said natural or artificial insult. The artificial insult comprises chemical insult, radiation insult, surgical insult, or a combination thereof. Natural insults to reproductive system occurs as a consequence of aging, genetic background, physiological factors, environmental factors, or other developmental and genetic factors.

10 According to an object of the invention, the artificial insult comprises chemical insults, including for example, cytotoxic factors, chemotherapeutic drugs, hormone deprivation, growth factor deprivation, cytokine deprivation, cell receptor antibodies, and the like. Chemotherapeutic drugs include 5FU, vinblastine, actinomycin D, etoposide, cisplatin, methotrexate, doxorubicin, among others.

15 In accordance with another object of the invention, the artificial insult comprises radiation insult, including ionization radiation, x-ray, infrared radiation, ultrasound radiation, heat, or a combination thereof. Radiation is administered to a patient through an invasive radiation therapy, a non-invasive radiation therapy, or both.

20 Protection of female's reproductive system is achieved in females in all age groups consisting of pre-reproductive age, reproductive age and post-reproductive age group.

One of the preferred agents of this invention is a small molecule compound comprising lysophospholipid. More preferably the lysophospholipid is a sphingolipid

compound, or an analog thereof. The most preferred agent of the invention is the compound of sphingosine-1-phosphate, or an analog thereof. The agent is administered *in vitro*, *ex vivo*, or *in vivo*. Preferred routes of administration include, orally, intravascularly, intraperitoneally, intra-uterine, intra-ovarian, subcutaneously, intramuscularly, rectally, topically, or a combination thereof. Intra-ovarian administration is achieved by methods, including, for example, by direct injection into the ovary. The injection is made to the ovary *in vivo* or *ex vivo*.

According to another object of the invention, a method of preserving, enhancing, or reviving ovarian function in female mammals is disclosed. This method comprises administering to female mammals an effective amount of a composition comprising sphingosine-1-phosphate, or an analog thereof. The ovarian functions include fertility and normal menstrual cyclicity.

Yet another object of the invention is a method to prevent or ameliorate menopausal syndromes. Menopausal syndromes within the scope of this invention include somatic disorders, cognitive disorders, emotional disorders, and the like. The agent of the invention is administered on a regular daily, weekly, biweekly, monthly or annual intervals in order to achieve the intended therapeutic objective.

According to another object of the invention, an *in vitro* fertilization method is disclosed that comprises (a) obtaining at least one oocyte from a mammal; (b) incubating said oocyte in a medium containing sphingosine-1-phosphate, or an analog thereof, in an amount sufficient to maintain viability of said oocyte in culture; (c) fertilizing *in vitro* said oocyte with sperm to produce at least one fertilized oocyte (zygote); (d) culturing said fertilized oocyte to produce an embryo; and (e) transferring at least one embryo to the uterus of said

mammal, wherein said at least one embryo develops to term in said mammal.

III. Brief Description of The Figures

FIGURE 1. Postnatal oocyte hyperplasia results from *ASMase* gene disruption. Number of non-atretic primordial, primary and small preantral follicles in young adult (day 42 postpartum) wild-type (hatched bars) and *ASMase* gene knockout (solid bars) female mice (mean \pm SEM, n=3 mice per genotype; P<0.05 versus respective wild-type value).

FIGURE 2. *ASMase*-deficiency or sphingosine-1-phosphate treatment attenuates programmed cell death in female germline during fetal gametogenesis. (A) Rate of programmed cell death in germline of ovaries obtained from wild-type (+/+) or *ASMase*-mutant (-/-) female fetuses following *in vitro* culture without hormonal support. Each data point represents the mean (\pm SEM) number of non-apoptotic germline remaining per ovarian section, and the results are the combined data from 6 fetal ovaries per genotype (P<0.05 versus respective wild-type value). (B) Effects of fumonisin-B1 (FB1) and S1P on germ cell survival in wild-type fetal ovaries cultured for 72 hours without hormonal support (mean \pm SEM, n=6 fetal ovaries per group). Over one-half of the starting population of germline (0 h or Time 0) is preserved after 72 hours of hormone deprivation by either *ASMase* gene disruption or by S1P treatment.

FIGURE 3. Cell autonomous nature of the germline programmed cell death defect caused by *ASMase* gene disruption or S1P treatment. Representative analysis of cellular morphology (A, B) and of DNA integrity as assessed by the comet assay (C, D) in pools of non-apoptotic oocytes (*ASMase*-deficient oocytes treated with doxorubicin or DXR; A, C)

and apoptotic oocytes (wild-type oocytes treated with DXR; B, D). (E) Apoptotic cell death response in wild-type (+/+) versus *ASMase*-deficient (-/-) oocytes cultured without (control, CON) or with 200 nM DXR for 24 hours, or in wild-type oocytes microinjected with human recombinant ASMase or human recombinant Bax. Mean \pm SEM from 3 or more independent experiments with the total number of oocytes used per group indicated over the respective bar, $P < 0.05$ versus respective wild-type value, N.D., none detected. For both ASMase and Bax microinjection, a significant ($P < 0.05$) increase in apoptosis was observed versus those levels observed in comparable numbers of vehicle-injected oocytes cultured in parallel ($20 \pm 5\%$; mean \pm SEM, $n=3$ or more independent experiments).

FIGURE 4. Complete protection of the female germline from radiation-induced death *in vivo* by S1P administration. Morphometric analysis of the number of non-atretic oocyte-containing follicles at the four indicated stages of development remaining in vehicle (PET)- or S1P-treated ovaries 14 days after a single treatment with 0.1 Gy of ionizing radiation (mean \pm SEM, $n=3$ mice; $P < 0.05$ versus 0 μ M S1P receiving radiation treatment; N.S., not significantly different).

▨	No radiation	} 0.1 Gy radiation
▤	0 μ M S1P	
■	50 μ M S1P	
□	200 μ M S1P	

IV. Detailed Description Of The Invention

This invention, as described herein, relates that compositions containing a novel therapeutic agent, administered *in vivo* or used *in vitro*, which protects female reproductive system from stress signals or insults induced by natural or artificial factors.

Apoptosis is a mechanism by which cells are programmed to die under a wide range of physiological, biochemical and developmental stimuli. Apoptosis is also an important cellular response to a large variety of stress signals, induced by natural or artificial factors. Acid sphingomyelinase (*ASMase*) gene disruption is shown to suppress normal apoptotic deletion of oocytes, leading to ovarian hyperplasia. *Ex vivo*, *ASMase*^{-/-} oocytes or wild-type oocytes treated with an agent, capable of antagonizing one or more *ASMase* gene products, resist developmental and anticancer treatment-induced apoptosis, thereby confirming cell autonomy of the death defect.

The invention, as disclosed and described herein, provides for a germ cell-autonomous death defect caused by *ASMase*-deficiency. Cell autonomous death is reversed by inhibition of *ASMase* gene products, which inhibition causes a significant hyperplasia of the female germline during fetal ovarian development. These data, demonstrate that antagonizers of *ASMase* gene products confer significant protection against natural or artificial insults on oocytes *in vivo*, or *in vitro* and, therefore, offer a new route for rapid therapeutic development to combat premature ovarian failure, and to prolong ovarian function and fertility in women.

At present, how antagonizers of *ASMase* gene products exert their pro- and anti-apoptotic effects in a female reproductive system remains to be elucidated. Without being limited to any

specific mechanism of action underlying the invention described herein, one possible mechanism is that a stepwise program of cell death is activated in germline by both physiologic and pathologic stimuli, with alterations in the sphingolipid rheostat serving as an initial signal transduction pathway. Indeed, S1P has been shown to prevent activation of downstream executioner caspases in Jurkat T-cells exposed to short-chain ceramide analogs (Cuvillier *et al.*, *J. Biol. Chem.* 273,2910(1998)), and ceramide has recently been implicated as a facilitator of Bax-induced cytochrome c release from mitochondria (Pastorino *et al.*, *J. Biol. Chem.* 274, 31734 (1999)).

The direct connection between ceramide and Bax is especially relevant to the present invention since Bax-deficient oocytes are, like *ASMase*-deficient oocytes, resistant to cancer therapy-induced apoptosis (Perez *et al.*, *Nature Med.* (1997) *id.*) Furthermore, microinjection of human recombinant Bax protein into oocytes duplicates the pro-apoptotic effects of both human recombinant *ASMase* microinjection and anti-cancer drug treatment (Fig. 3E).

The *ASMase* antagonizers, or the "agent" according to this invention, include any compound, that suppresses or inhibits activity and/or expression of one or more acid sphingomyelinase (*ASMase*) gene products *in vitro*, *ex vivo*, or *in vivo*. The agent comprises, for example, any lipid, lysophospholipid, sphingolipid, protein, peptide, polypeptide, nucleic acid molecule, including DNA, RNA, DNA/RNA hybrids or an antisense molecule, small molecules, antibiotics, and the like. The terms protein, peptide, and polypeptide are used interchangeably herein.

A preferred agent according to the invention is a small molecule. In a more preferred embodiment of the invention, the agent comprises lysophospholipids, and most preferably, the agent is sphingosine-1-phosphate (S1P), or an analog thereof. Examples of analogs of

sphingosine-1-phosphate, include but are not limited to, N,N-dimethylsphingosine-1-phosphate; N,N,N-trimethylsphingosine-1-phosphate; N-acetylsphingosine-1-phosphate; N-acylsphingosine-1-phosphate; sphingosine-1,3-diphosphate; sphingosine-3-phosphate; sphingosine-1-thiophosphate; N,N-dimethylsphingosine-1-thiophosphate; N,N,N-trimethylsphingosine-1-thiophosphate; or pharmaceutically acceptable salts thereof.

Sphingosine-1-phosphate is shown to be completely safe and without side effects on the ovaries. In one general embodiment of the invention, as disclosed herein, *in vivo* administration of the agent of the invention prior to an artificial insult resulted in a significant preservation of the germ cell reserve with complete protection of the quiescent (primordial) and growing (primary, preantral) follicle populations in ovaries exposed to the insult.

According to one general embodiment of the invention, artificial insults are the consequence of a therapy against a disease or a disorder. The disease or disorder comprises, for example, cancer, rheumatoid arthritis, angioplasty, or restenosis. Cancer includes, for example, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chondroma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma,

hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, acute lymphocytic leukemia and acute myelocytic leukemia, chronic leukemia and polycythemia vera, lymphoma (Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, or immunoglobulin heavy chain diseases.

Artificial insults, according to the invention described herein, include chemical, radiation, and surgical insults. Examples of chemical insults include, cytotoxic factors, chemotherapeutic drugs, hormone deprivation, growth factor deprivation, cytokine deprivation, cell receptor antibodies and the like. Further non-limiting examples include TNF-alpha, TNF-beta, IL-1, INF-gamma, IL-2, insulin-like growth factor, transforming growth factor B1, vascular endothelial growth factor, fibroblast growth factor, 5FU, vinblastine, actinomycin D, etoposide, cisplatin, methotrexate, doxorubicin, and the like.

In accordance with another embodiment of the invention, the insult is a radiation insult. It is shown that germline of female mammals exposed to radiation are seriously damaged and administration of the composition of the invention *in vivo*, *in vitro*, or *ex vivo* protects oocytes from destruction induced by a therapeutically-relevant dose of ionizing radiation.

Radiation insult, according to the invention disclosed herein, encompasses both non-invasive (external) and invasive (internal) radiation therapies. In an external radiation therapy, treatment is affected by radiation sources outside the body, whereas in an invasive radiation therapy treatment is affected by radiation sources planted inside the body. The representative diseases treated by non-invasive or invasive radiation therapy include, for example, cancer, rheumatoid arthritis, angioplasty, or restenosis.

Invasive radiation therapy encompasses, for example, selective internal radiation therapy (SIRT), incorporation of the radioactive materials into small particles, microspheres, seeds, wires and the like. These objects are directly implanted into the various tissue, organs, or their respective arterial blood supply within the body.

5 Various methods for introducing radiation into an area treated for stenosis are known. Some methods deliver radiation in a solid medium, while others utilize liquid sources. For example, a procedure in reducing the restenosis rate is the introduction of radiation energy into the interior of the vessel. This procedure, known as "intravascular radiation therapy" (IRT) has been shown to inhibit fibroblast and smooth muscle cell hyperplasia.

10 U.S. Patent No. 5,059,166, issued to Fischell, discloses an IRT method that relies on a radioactive stent that is permanently implanted in the blood vessel after completion of the lumen opening procedure. U.S. Patent No. 5,302,168, issued to Hess, teaches use of a radioactive source contained in a flexible catheter. U.S. Patent No. 5,503,613, issued to Weinberger, uses a liquid filled balloon to guide a solid source wire to a treatment site. U.S. Patent No. 5,616,114, issued to Thornton *et al.*, describes an apparatus and method for delivering liquid radiation into a balloon-tipped catheter. Radiation therapies disclosed by
15 aforementioned patents, are disclosed merely as examples of radiotherapeutic regimens used to treat patients and are non-limiting.

20 The use of radioactive material in connection with therapies, such as those disclosed above, creates a risk of harmful exposure, both to the medical personnel and to patients. Precautionary measures need to be taken to protect against the harm caused by the leakage of liquid radiation into the blood stream during these therapies. Sensitive organs, such as the

ovaries, are inevitably damaged depending on the invasiveness of the procedure used. The invention disclosed herein protects ovaries of both patients and medical personnel from a risk of harm caused by exposure to radiation during such therapies.

Radiation is emitted from a variety of radionuclides. These radionuclides encompass, for example, beta-ray emitters, gamma-ray emitters, or a radionuclide that emits both beta-ray and gamma-ray. Further examples of radionuclides include, Strontium 90, Iridium 192, Phosphorous 32, Rhenium 186, Rhenium 188, ¹⁹⁸Au, ¹⁶⁹Er, ¹⁶⁶Ho, ¹⁵³Sm, and ¹⁶⁵Dy, which are chosen according to the purpose of treatment.

Other radiation sources include sources used in nuclear magnetic resonance diagnosis in which the central ion of the complex salt must be paramagnetic. In particular, the radiation sources use the divalent and trivalent ions of the elements of atomic numbers 21-29, 42, 44 and 58-70. Suitable ions are, for example, the chromium(III), manganese(II), iron(II), nickel(II), copper(II), praseodymium(III), neodymium(III), samarium(III), ytterbium(III), gadolinium(III), terbium(III), dysprosium(III), holmium(III), erbium(III), and iron(III).

According to another embodiment of the invention disclosed herein, radiation insult includes ultrasound radiation. Ultrasound radiation is administered to patients, either alone or in combination with other therapies, for example, hormonal therapy, chemotherapy, or surgery. The therapeutic regimen is applied either preoperatively, *i.e.*, to the tumor in situ or postoperatively, in the region of the tumor after removal of the primary cancerous lesion. The ultrasound therapy comprises both the invasive and non-invasive ultrasound treatments. The dosage of ultrasonic energy applied is, for example, above 22.5 watt/sec, and has a frequency in the range of, for example, about 1 KHz to about 3 MHz.

According to another embodiment of this invention, radiation insult includes, x-ray,

infrared, and heat. Heat is used to selectively induce apoptosis in intended cells or tissues. Preferably heat is used to treat inflammation. The term inflammation includes inflamed atherosclerotic plaques, restenosis, and arteritis such as that found in systemic lupus, myocarditis of the autoimmune etiology, arteriovenous fistulea, dialysis grafts or other vascular prosthesis. The phrase "treating inflammation" also includes treating a region of a vein prior to or after balloon angioplasty, or related interventions that could result in inflammation and subsequent thrombosis, acute closure or restenosis.

Heat may be transferred to the target cells by a variety of methods. For example, heat is transferred into an inflamed plaque in a blood vessel by means of a catheter, stent, or liquid heat. Catheter or stents are heated electrically or with microwave or radio frequency radiation or other means. Heat is also generated from internal or external devices, such as radiofrequency sources outside the body. The present invention protects ovaries from the risk of over-exposure to heat waves or liquid heat during heat therapy.

Natural insults, as defined herein, include damages resulting from physiological, biochemical or developmental processes occurring in a female body. A manifest natural insult is apoptosis due to aging. Natural insults are influenced, for example, by genetic background of the female, environmental affects, or both. The functional life span of female gonads is defined by the size and rate of depletion of the endowment of oocytes enclosed within follicles in the ovaries at birth. This continuous loss of oocytes throughout life, referred to by many as the female biological clock, is driven by a genetic program of cell death that is controlled by physiological and biochemical pathways and players and is conserved from worms to humans (Morita & Tilly (1999) *id.*) This invention, as disclosed herein, demonstrates the effect of antagonizers of *ASPMase* gene products in combating

normal or pre-mature germ cell depletion in a female mammal.

Without being limited to any specific mechanism of action underlying the invention described herein, one possible mechanism for the effect of antagonizers of *ASMAse* gene products is through preventing apoptosis of granulosa cells as well as, or instead of, directly preventing apoptosis of oocytes. Granulosa cells support, nourish, and help to mature oocytes throughout postnatal life.

Examples of disease and disorders resulting from a natural insult include, disturbances in menstruation, abnormal uterine bleeding, abnormal ovulatory cycles, amenorrhea, pelvic pain, sexual dysfunction, in fertility, menstrual cyclicity, and pre-mature menopause among others.

Other insults include surgical insults wherein a woman's reproductive system, in part or in whole, is surgically removed. In particular, hormonal imbalance, resulting from the removal of one or both ovaries, is fully or partially restored by administration of the therapeutic agent of the invention.

Reproductive system includes any cell, tissue, organ, and tract that are involved in part or in whole in sexual reproduction. Cells include variety of somatic cells, for example, granulosa cells that nourish and mature oocytes, as well as germ cells.

Included withing the scope of this invention are methods to protect women's ovaries from natural and artificial insults, not only to keep them fertile, but also to preserve enough ovarian function to prevent menopause and its associated disorders. Women are subject to natural or artificial insult in any age group. These age groups are pre-reproductive, reproductive or post-reproductive age groups. Pre-mature menopausal syndromes are initiated by a wide variety of artificial or natural conditions. Menopausal disorders, include,

for example, somatic disorders such as osteoporosis, cardiovascular disease, somatic sexual dysfunction, loss of libido; cognitive disorders, such as loss of memory; emotional disorders, such as depression, and the like.

5 The composition of the invention is administered on a continuous or semi-continuous, or temporary basis, depending on the type of insult and objectives of the therapy intended. For example, if protection of the reproductive system from long term natural insults is intended, administration of the composition of this invention on a continuous or semi-continuous basis is preferred. In a continuous administration, the composition is generally administered regularly, on a predetermined interval, for an indefinite period of time. Predetermined intervals comprise daily, weekly, biweekly, or monthly, or yearly intervals.

10 If protection from artificial insults are intended both short term and long term administration are suggested, depending on the type of insult and the objective of the therapy intended. An example of a short term administration is the administration to protect ovaries from radiation or chemical insults. In short term administration, the composition is administered, at least once, in a period of from about thirty days prior to immediately prior to exposure to the insult. More preferably the composition is administered from about fifteen days to about two days, and most preferably from about seven days to about two hours prior to exposure to the insult. The administration of the composition is terminated prior to ovarian exposure to the insult, or it is continued during exposure or after the exposure is terminated.

15 20 The dosage of the therapeutic agent is adjusted according to, for example, the duration and the objective of the treatment intended. A lower dosage of the agent is required in a more prolonged and continuous administration.

The administration is achieved *in vivo*, *in vitro* or *ex vivo*. The *in vivo* administration encompasses orally, intravascularly, intraperitoneally, intra-uterine, intra-ovarian, subcutaneously, intramuscularly, rectally, topically, or a combination thereof. Intra-ovarian administration is achieved by several methods, including, for example, by direct injection into the ovary. The injection is made to the ovary *in vivo* or *ex vivo*.

According to another aspect of this invention, an *in vitro* fertilization method is described that uses the therapeutic agent of this invention to protect the viability of female germline at different stages of *in vitro* fertilization. These stages, include *in vivo*, *ex vivo*, and *in vitro* periods of fertilization and pregnancy. *In vivo* stages of fertilization and pregnancy include, for example, one or more of the following periods: the period prior to isolation of oocytes, the period after implantation of the embryo in the uterus, and the period during pregnancy. *In vitro*, and *ex vivo* stages include, for example, one or more of the following: cryopreservation of oocytes, culture or growth of oocytes prior to fertilization, fertilization stage, culture or growth of embryo post-fertilization.

Oocytes isolated from women are at different stages of development and are either mature or immature. Immature oocytes reach maturity *in vitro* or *in vivo* conditions. *In vitro* fertilization, according to the invention, is achieved by the use of a mammal's own oocytes or a different mammal's oocytes. After the embryo is implanted in the subject mammal, *in vivo* administration of the therapeutic agent is terminated, or it is continued for a time period thereafter to ensure continued viability and normal development of the embryo *in vivo*.

In vitro fertilization method, according to the invention disclosed and described herein, increases the chances of successful fertilization, pregnancy and normal development of the embryo in the uterus. Furthermore, it ensures availability of immature or mature

oocytes for fertilization, and makes it possible to preserve fertility and increases availability of donor oocytes for women who do not have their own functional oocytes.

Also embraced within the scope of this invention are compositions comprising one or more agents of the invention in association with one or more non-toxic, pharmaceutically acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients.

According to an embodiment of the invention, the agent is combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanolic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose.

Formulations for parenteral administration are, for example, in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions are prepared, for example, from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cotton seed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

The compositions of the invention are adapted to be administered by any suitable route, and in a dose effective for the treatment intended. Therapeutically effective doses of the composition required to prevent or preserve the female reproductive system from insults are readily ascertained by one of ordinary skill in the art.

5 For oral administration, the composition is in the form of, for example, a tablet, capsule, suspension or liquid. The composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. Preferably, the oral units contain an amount of active ingredient from about 1 to 1000 mg, more preferably from about 25 to 500 mg, and most preferably from about 100 to 250 mg. A suitable daily dose may vary widely, however, a dose of from about 0.01 to 3000 mg/kg body weight, or from about 0.1 mg to about 100 mg/kg of body weight per day is preferred. A more preferred dosage will be a range from about 1 mg to about 100 mg/kg of body weight. Most preferred dosage is a dosage in a range from about 1 to about 50 mg/kg of body weight per day.

15 The dosage regimen of the agents and/or compositions of this invention is selected in accordance with a variety of factors and thus may vary widely. A main factor to consider is the objective of therapy, for example, protecting female germline from radiation or chemotherapy, prolonging fertility, preventing menopause, preserving normal menstrual cyclicity, ameliorating or preventing post-menopausal conditions, are among many
20 therapeutic objectives that are intended and encompassed within the scope of the invention. Other factors include, for example, the age, weight, severity and type of the insult, the route of administration, and the type of therapeutic agent employed.

The invention will be more fully understood by reference to the following examples.

These examples are not to be construed in any way as limiting the scope of this invention.

All literature cited herein is specifically incorporated by reference.

V. *Examples*

Example 1. **Histomorphometric Evaluation of Oocyte Endowment**

Ovaries are fixed (0.34 N glacial acetic acid, 10% formalin, 28% ethanol), embedded in paraffin, and serially sectioned (8 μ M). The serial sections from each ovary are aligned in order on glass microscope slides, stained with hematoxylin/picric methyl blue, and analyzed for the number of healthy (non-atretic) oocyte-containing primordial, primary and small preantral follicles as described by Perez *et al. Nat. Genet.* (1999) *id.* incorporated by reference herein in its entirety.

Example 2. **Histomorphometric Evaluation of Wild Type and *ASMase* ^{-/-} Ovaries**

ASMase ^{-/-} mice are generated as described by Horinouchi *et al., Nat. Genet.* 10, 288 (1995), incorporated herein by reference in its entirety. The histomorphometric evaluation of the oocyte endowment of wild type mice and *ASMase* ^{-/-} sisters shows that sphingomyelin hydrolysis is a key event in generating death signals in the developing female germline. Compared with their wild-type sisters, *ASMase* ^{-/-} females possess over 1.1 X 10³ more quiescent oocyte-containing primordial follicles per ovary, as well as significant hyperplasia of the growing (primary and small preantral) follicle populations. Results are

presented in Table 1 and Fig. 1.

Table 1. Postnatal Oocyte Hyperplasia Results From *ASMase* Gene Disruption

Follicles	+/+	-/-	P value
Primordial	19120±602	30480±2397	P<0.01
Primary	707±93	1573±141	P<0.01
Preantral	13±13	160±46	P<0.05

Number of non-atretic oocyte-containing primordial follicles endowed in the ovarian reserve, and numbers of growing (primary and small preantral) follicles, in wild-type (+/+) and *ASMase*-mutant (-/-) female mice at day 4 postpartum (mean ± SEM, n=3 mice per genotype).

The ovarian oocyte reserve remains significantly elevated in *ASMase* -/- female mice in young adult life (Fig. 1), well prior to the onset of any organ abnormalities or Niemann-Pick disease-like symptoms that occurs in *ASMase* -/- mice during postnatal life.

To determine the basis of the extensive oocyte hyperplasia in *ASMase*-/- neonates, fetal ovaries are harvested from wild-type and mutant mice at embryonic day 13.5 (e13.5) for *in vitro* culture as a model to recapitulate the events surrounding germline death that occurs as a normal component of female gametogenesis. A time-dependent activation of programmed cell death is observed in germline of wild-type fetal ovaries cultured without hormonal support for up to 72 hours (Fig. 2A). By comparison, the rate of germ cell apoptosis is significantly attenuated in *ASMase*-deficient fetal ovaries cultured in parallel (Fig. 2A). These findings indicate that there exists an ovarian-intrinsic cell death defect in the *ASMase*-deficient mouse, and point to enhanced survival of the developing germline during oogenesis as the mechanism underlying the enlarged oocyte pool seen in mutant

females at birth.

Example 3. Treatment With Ceramide Synthase Inhibitor

5 In order to show that sphingomyelin hydrolysis, as opposed to ceramide synthesis, is important for generating ceramide as a death signal, wild-type fetal ovaries are maintained *in vitro* for 72 hours and various concentrations (5-500 μ M) of a ceramide synthase inhibitor, fumonisin-B1 (FB1) are applied to these ovaries. The results show that this treatment does not alter survival rates in female germline (Fig. 2B). Importantly, however, and in support of the rheostat model, the reduced incidence of germ cell apoptosis conveyed by *ASMase*-deficiency is recapitulated by culturing wild-type fetal ovaries with increasing concentrations of S1P (Fig. 2B). Equivalent levels of *in vitro* germ cell survival are obtained by either *ASMase* gene knockout (Fig. 2A) or by S1P treatment (Fig. 2B).

15 Example 4. Cell Autonomous Nature of Response

To demonstrate that germline survival is a cell autonomous or a germline-intrinsic response, individual oocytes are isolated from adult wild-type and *ASMase* $-/-$ female mice, and are cultured *ex vivo* with or without the anti-cancer drug, doxorubicin (DXR), to induce apoptosis. In addition to assessments of cellular morphology and caspase activation, some oocytes in each group are processed for DNA cleavage analysis as an endpoint for cell death using the Trevigen Comet Assay kit. The apoptotic event is elicited in wild-type, but not *ASMase*-deficient, oocytes by DXR (Fig. 3E).

Example 5. Microinjection Experiment

Human recombinant acid sphingomyelinase is synthesized and purified as described by He *et al.*, *Biochim. Biophys. Acta* **1432**, 251 (1999), incorporated herein by reference in its entirety. Six picoliters of vehicle or of a 1 mg/ml stock of the enzyme are microinjected into single oocytes using a Zeiss Axiovert 135 inverted microscope equipped with Narishige micromanipulators and a PLI-100 pico-injector. Oocytes that survived the microinjection procedure (>75%) are then cultured and assessed for the occurrence of apoptosis. Furthermore, microinjection of human recombinant Bax protein into single oocytes and assessments of apoptosis are made as described by Perez, *et al.* (1997) *id.* Microinjection of human recombinant Bax protein into oocytes duplicates the pro-apoptotic effects of both human recombinant *ASMase* microinjection and anti-cancer drug treatment (Fig. 3E). For both *ASMase* and Bax microinjection, a significant ($P < 0.05$) increase in apoptosis is observed versus those levels observed in comparable numbers of vehicle-injected oocytes cultured in parallel ($20 \pm 5\%$; mean \pm SEM, $n=3$ or more independent experiments).

Example 6. *In vitro* oocyte cultures

Female mice (43 days of age post-partum; Charles River Laboratories, Wilmington, MA) are superovulated with 10 IU of equine chorionic gonadotropin (eCG or PMSG) followed by 10 IU of human chorionic gonadotropin 48 h later. Mature oocytes are collected from the oviducts 16 h after hCG injection. Cumulus enclosed oocytes are denuded by a 1-

min incubation in 80 IU/ml of hyaluronidase, followed by three washes with culture medium. The medium used for all culture experiments is human tubal fluid (Irvine Scientific, Santa Ana, CA) supplemented with 0.5% bovine serum albumin (BSA).

Oocytes are cultured in 0.1 ml drops of culture medium (8-10 oocytes/drop) under paraffin oil, an incubated with or without DXR (200 nM) and/or fumonisin-B1, sphingosine-1-phosphate or benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD-FMK) for 24 h at 37 C in a humidified atmosphere of 5% CO₂-95% air. At the end of the incubation period, oocytes are fixed, stained with Hoechst 33342 and checked microscopically for morphological changes characteristic of apoptosis (condensation, budding, cellular fragmentation, and chromatin segregation into apoptotic bodies). The percentage of oocytes that goes through apoptosis out of the total number of oocytes cultured per drop in each experiment is then determined, and all experiments are independently repeated four to ten times with different mice.

Example 7. *In vitro* Embryo Cultures

Female mice are superovulated with eCG followed hCG treatment (see above) and placed with fertile males immediately after hCG injection. Sixteen hours after mating, one-cell embryos (confirmed by the presence of two polar bodies) are harvested from the ampullae and denuded of cumulus cells by a 1-min hyaluronidase treatment. Embryos are then maintained *in vitro* in HTF supplemented with 0.5% BSA in absence or presence of 200 nM DXR. Under *in vitro* conditions, one-cell embryos progress to the morula stage of development within 72 h (see *in vitro* oocyte cultures above for details of methodology and

culture conditions). See, Perez *et al.*(1997) *id.*, incorporated by reference herein in its entirety.

Example 8. Bax-Null Mice

In vitro experiments: mature oocytes are harvested from wild-type and Bax-null adult female mice at approximately 6 weeks of age using the gonadotropin superovulation regimen described above. Following hyaluronidase removal of cumulus cells, oocytes are incubated for 24 h without or with 200 nM DXR, after which the occurrence of apoptosis is assessed and described under *in vitro* oocyte cultures.

In vivo experiments: age-matched adult wild-type and Bax-null female mice are given two intraperitoneal injections of DXR (10 mg/kg of body weight) 1 week apart, starting at approximately 8 weeks of age post partum. One week following the second injection, ovaries are collected, fixed, embedded in paraffin, serial-sectioned, and stained with hematoxylin/picric methyl blue. Follicular morphology and numbers of immature (primordial) follicles present in each ovary are then assessed as detailed previously.

Example 9. p53-Null Mice

Mature oocytes are collected from adult wild-type and p53 null female mice by superovulation, and incubated with or without 200 nM DXR for 24 h. Following culture, the occurrence of apoptosis is assessed as described above (see, Example 6: *in vitro* oocyte cultures).

Example 10. S1P Protection Against Radiation

Young adult (postpartum day 40) wild-type female mice are anesthetized, and dorsal incisions are made to retrieve and expose the ovaries. Five μ l of vehicle (PET) are injected into the bursa of one ovary of the pair while 5 μ l of a stock of either 0.5 or 2 mM S1P, prepared in PET, are injected into the bursa of the contralateral ovary. Based on an estimated bursai cavity volume of 50 μ l, the final concentrations of S1P in the bursal cavity for ovarian exposure following administration of the 0.5 and 2 mM stocks are approximately 50 and 200 μ M, respectively. The ovaries are returned to the peritoneal cavity, the incisions are sutured, and the mice are allowed to recover for a 2 hour pretreatment period prior to a single exposure to 0.1 Gy of abdominally-directed ionizing radiation. After two weeks, ovaries are collected, coded, and processed for histomorphometric evaluation of non-atretic oocyte-containing follicle numbers as described above (see Example 1). In the absence of irradiation, the number of follicles at any stage of development in S1P-treated ovaries does not significantly differ from the number of corresponding follicles in vehicle-treated ovaries.

Nearly complete destruction (LD_{80}) of the oocyte-containing primordial follicle pool is observed in vehicle-treated ovaries of mice two weeks after a single exposure to 0.1 Gy of ionizing radiation (Fig. 4). In contrast, *in vivo* administration of S1P two hours prior to irradiation resulted in a significant and dose-dependent preservation of the germ cell reserve, with complete protection of the quiescent (primordial) and growing (primary, preantral) follicle populations in ovaries exposed to the highest dose of S1P prior to irradiation (Fig. 4).

Moreover, since oocyte viability, growth and function are required for continued

development of follicles from a quiescent to mature state (see, Morita & Tilly (1999) *id.*,
incorporated herein by reference in its entirety), the observation that ovaries pretreated with
the highest dose of S1P prior to irradiation retained a completely normal distribution of
oocyte-containing follicles at all stages of development (*i.e.*, identical to the non-irradiated
controls) at two weeks post-irradiation (Fig. 4) suggests that the protected oocytes are indeed
viable and functional.

What Is Claimed Is:

1. A method of protecting female reproductive system against a natural or artificial insult comprising: administering a composition comprising an agent that antagonizes one or more acid sphingomyelinase (*ASMase*) gene products, in an amount sufficient to protect said female reproductive system from pre-mature aging or destruction caused by said natural or artificial insult.

2. The method of claim 1, wherein said artificial insult comprises chemical insult, radiation insult, surgical insult, or a combination thereof.

3. The method of claim 1 wherein said natural insult is a consequence of aging, genetic background, physiological factors, environmental factors, or a combination thereof.

4. The method of claim 2, wherein said chemical insult comprises cytotoxic factors, chemotherapeutic drugs, hormone deprivation, growth factor deprivation, cytokine deprivation, cell receptor antibodies, or a combination thereof.

5. The method of claim 4, wherein said chemotherapeutic drug comprises; 5FU, vinblastine, actinomycin D, etoposide, cisplatin, methotrexate, doxorubicin, or a combination thereof.

6. The method of claim 2, wherein said radiation insult comprises ionization radiation, x-ray, infrared radiation, ultrasound radiation, heat, or a combination thereof.

7. The method of claim 2, wherein said radiation insult comprises an invasive radiation therapy, a non-invasive radiation therapy, or both.

8. The method of claim 1, wherein said female reproductive system comprises ovaries.

9. The method of claim 1, wherein said female reproductive system comprises oocytes.

10. The method of claim 1, wherein said female is in a reproductive age.

11. The method of claim 1, wherein said female is in a pre-reproductive age.

12. The method of claim 1, wherein said female is in a post-reproductive age.

13. The method of claim 1, wherein said agent comprises a small molecule compound.

14. The method of claim 13, wherein said small molecule compound comprises lysophospholipid.

15. The method of claim 14, wherein said lysophospholipid is a sphingolipid compound, or an analog thereof.

16. The method of claim 15, wherein said sphingolipid compound is sphingosine-1-phosphate, or an analog thereof.

17. The method of claim 1, wherein said composition is administered at least once from about fifteen days to about two days prior to exposure to said insult.

18. The method of claim 17, wherein said composition is administered at about seven days to about two hours prior to exposure to said insult.

19. The method of claim 3, wherein said composition is administered regularly for an indefinite period of time.

20. The method of claim 1, wherein said composition is administered orally, intravascularly, intraperitoneally, subcutaneously, intramuscularly, intra-uterine, intra-ovarian, rectally, topically, or a combination thereof.

21. The method of claim 1, wherein said artificial insult is a result of a therapy

against a disease or a disorder.

22. The method of claim 21, wherein said disease or disorder comprises, cancer, rheumatoid arthritis, angioplasty, or restenosis.

23. The method of claim 22, wherein said cancer comprises; colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chondroma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, acute lymphocytic leukemia and acute myelocytic leukemia, chronic leukemia and polycythemia vera, lymphoma (Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain diseases, or a combination thereof.

24. The method of claim 1, wherein said administration is an *in vitro* administration.

25. The method of claim 1, wherein said administration is an *ex vivo* administration.

26. The method of claim 1, wherein said administration is an *in vivo* administration.

27. A method of preserving, enhancing, or reviving ovarian function in mammals comprising: administering to said mammal an effective amount of a composition comprising

sphingosine-1-phosphate, or an analog thereof.

28. The method of claim 27, wherein said mammal is in a reproductive age.

29. The method of claim 27, wherein said mammal is in a pre-reproductive age.

30. The method of claim 27, wherein said mammal is in a post-reproductive age.

5 31. The method of claim 27, wherein said ovarian function comprises fertility, or normal menstrual cyclicity.

32. The method of claim 27, wherein said mammal is a woman.

33. A method of preventing or ameliorating menopausal syndromes in women, comprising administering to women, at predetermined intervals, a composition comprising sphingosine-1-phosphate, or an analog thereof.

34. The method of claim 33, wherein said women are pre-menopausal or post-menopausal women.

35. The method of claim 33, wherein said menopausal syndromes comprise somatic disorders, cognitive disorders, emotional disorders, or a combination thereof.

15 36. The method of claim 33, wherein said predetermined interval comprises daily, weekly, biweekly, or monthly intervals.

37. A method for *in vitro* fertilization of a mammal comprising

(a) obtaining at least one oocyte from a mammal;

20 (b) incubating said oocyte in a medium containing a composition comprising sphingosine-1-phosphate, or an analog thereof, in an amount sufficient to maintain viability of said oocyte in culture;

(c) fertilizing *in vitro* said oocyte with sperm to produce at least one fertilized oocyte;

d) culturing said fertilized oocyte to produce an embryo; and

e) transferring at least one embryo to the uterus of said mammal,

wherein said at least one embryo develops to term in said mammal.

38. The method of claim 37, wherein said at least one oocyte is immature when
5 obtained from said mammal and becomes mature in step (b).

39. The method of claim 37, wherein said mammal is human.

40. The method of claim 38, wherein said immature oocyte is cultured for about five
to about seven days at said step (b).

41. The method of claim 37, wherein prior to said step (b) said at least one oocyte
is cryopreserved in a cryopreservation medium containing said composition.

42. The method of claim 37, wherein said composition is additionally present in
steps (c) and (d).

43. The method of claim 37, wherein said composition is added continuously or
periodically to said culture media.

44. The method of claim 37, wherein mammal of step (a) is the same or different
from the mammal of step (d).

45. The method of claim 37, wherein said mammal is a woman.

ABSTRACT

Described are methods for protecting the female reproductive system against natural and artificial insults by administering to women a composition comprising an agent that antagonizes one or more acid sphingomyelinase (*ASMase*) gene products. Specifically, methods disclosed herein serve to protect women's germline from damage resulting from cancer therapy regimens including chemotherapy or radiotherapy. In one aspect, the method preserves, enhances, or revives ovarian function in women, by administering to women a composition containing sphingosine-1-phosphate, or an analog thereof. Also disclosed are methods to prevent or ameliorate menopausal syndromes and to improve *in vitro* fertilization techniques.

DC313692v2

References

1. Hannun, *Science*, 274:1855 (1996).
2. Cuvillier *et al.*, *Nature*, 381:800 (1996).
3. Hofmann & Dixit, *Trends Biochem. Sci.*, 23:374 (1998).
4. Watts *et al.*, *Cell Death Differ.*, 6:105 (1999).
5. Horinouchi *et al.*, *Nat. Genet.*, 10:288 (1995).
6. Perez *et al.*, *Nat. Med.*, 3:1228 (1997).
7. Bergeron *et al.*, *Genes Dev.*, 12:1304 (1998).
8. Morita *et al.*, *Mol. Endocrinol.*, 13:841 (1999).
9. Reynolds, J. *Nat. Cancer Inst.*, 91:664 (1999).
10. Morita & Tilly, *Dev. Biol.*, 213:1-17 (1999).
11. Perez *et al.*, *Nat. Genet.*, 21:200 (1999).
12. Morita *et al.*, *Endocrinology*, 140:941 (1999).
13. Bose *et al.*, *Cell*, 82:405 (1995).
14. Merrill *et al.*, *Toxicol. Appl. Pharmacol.*, 142:208 (1997).
15. Perez *et al.*, *Mol. Hum. Reprod.*, 5:414 (1999).
16. Van Brocklyn *et al.*, *J. Cell Biol.*, 142:229 (1998).
17. Van Brocklyn *et al.*, *J. Biol. Chem.*, 274: 4626 (1999).
18. Edsall *et al.*, *J. Neurosci.*, 17:6952 (1997).
19. Goetzl & An, *FASEB J.*, 12:1589 (1998).
20. Hla *et al.*, *Biochem. Pharmacol.*, 58:201 (1999).
21. Gosden, *Nature*, 383:485 (1996).
22. Dong *et al.*, *Nature*, 383:531 (1996).
23. Tilly & Robles in: *Molecular Biology in Reproductive Medicine*, Fauser *et al.*, (Parthenon, New York, 1999), Chapter 5, pp. 79-101.

24. Briggs *et al.*, in: *Molecular Biology in Reproductive Medicine*, Fauser *et al.*, (Parthenon, New York, 1999) Chapter 12, pp. 251-269.
25. Ko & Prives, *Genes Dev.*, 10:1054 (1996).
26. Ding & Fisher, *Crit. Rev. Oncog.*, 9:83 (1998).
27. Cuvillier, *J. Biol. Chem.*, 273:2910 (1998).
28. Pastorino *et al.*, *J. Biol. Chem.*, 274:31734 (1999).
29. He *et al.*, *Biochim. Biophys. Acta.*, 1432:251 (1999).
30. Jürgensmeier *et al.*, *Proc. Natl. Acad. Sci. USA*, 95:4997 (1998).
31. Tilly & Johnson in: *Apoptosis and Cancer Chemotherapy*, Hickman & Dive, (Humana Press, Totowa, New Jersey), Chapter 17, pp. 257-273.
32. Kolesnick & Krönke, *Annu. Rev. Physiol.*, 60:643 (1998).
33. S. Spiegel, *J. Leukoc. Biol.*, 65:341 (1999).
34. S. Spiegel *et al.*, *Ann. N.Y. Acad. Sci.*, 845:11 (1998).
35. Adams & Cory, *Science* 281, 1322 (1998).
36. Green, *Cell* 94, 695 (1998).
37. Thornberry & Lazebnik, *Science* 281, 1312 (1998).
38. Reed, *Oncogene* 17, 3225 (1998).
39. Korsmeyer, *Cancer Res.* 59, 1693 (1999).
40. Tilly *et al.*, *Endocrinology* 136, 1394 (1995).
41. Keren-Tal *et al.*, *Exp. Cell Res.* 218, 283 (1995).
42. Makrigiannakis *et al.*, *J. Clin. Endocrinol. Metab.* 85, 449 (2000)).
43. Tilly *et al.*, *Endocrinology* 136-232 (1995).
44. Ratts *et al.*, *Endocrinology* 136, 3665 (1995).
45. Knudson *et al.*, *Science* 270, 99 (1995).

46. Kugu *et al.*, *Cell Death Differ.* 5, 67 (1998).
47. Flaws *et al.*, *Endocrinology* 136, 5042 (1995).
48. Maravei *et al.*, *Cell Death Differ.* 4, 707 (1997).
49. Boone & Tsang, *Biol. Reprod.* 58, 1533 (1998).
50. Martimbeau & Tilly, *Clin. Endocrinol.* 46, 241(1997)).





Figure 1/4

A



B




Figure 2a

Figure 2b

Figure 3a




Figure 3c




Figure 3b




Figure 3d




Figure 3e




Figure 3/4

Number of non-atretic
follicles/ovary




Figure 4/4